

## CLAIMS

1. **Topical treatment of psoriasis with formulations (creams, gels,...) to accomplish non-physiologic high concentrations of Epidermal Growth Factor (EGF), which can down-regulate the expression of the EGF-Receptor .**
2. **Psoriasis treatment with topical formulations ,containing EGF in concentrations of 0.01 to to 50 micrograms/ gram.**
3. **Topical formulations containing 0.5-20 microgram EGF / gram of formulation .**
4. **Topical creams , containing 0.1-3% sulfadiazine and 0.5-20 micrograms EGF / gram for the treatment of psoriasis.**
5. **Topical formulations, containing anti-inflammatory products , in combination with epidermal growth factor.**
6. **Topical formulations, containing EGF in combination with anti-inflammatory products and other dermatologically-beneficial products , for the treatment of psoriasis.**
7. **Topical formulations , containing 10 µg EGF and 1% of sulfadiazine for the treatment of psoriasis.**
8. **Systemic treatment of psoriasis patients with 0.001 – 10 microgram of EGF / kg.**
9. **Topical and systemic treatment of psoriasis patients with precursor molecules of epidermal growth factor ,such as fibroblast growth factor.**
10. **Treatment with products, with similar biological action as EGF, such as urogastrone or fractions of the EGF molecule.**

002090 82648560